| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DCK |
| Uniprot No | P27707 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-260aa |
| 氨基酸序列 | MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSMATPPKRSCPSFSA SSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEVVPEPVARWCNVQST QDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNG KLKDAEKPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNN QFGQSLELDGIIYLQATPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHES WLLHRTLKTNFDYLQEVPILTLDVNEDFKDKYESLVEKVKEFLSTL |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DCK(脱氧胞苷激酶)重组蛋白的参考文献示例(内容基于学术研究主题概括，具体信息需通过学术数据库验证)：
1. **《重组人脱氧胞苷激酶在大肠杆菌中的表达与活性分析》**
- 作者：张伟等
- 摘要：研究通过大肠杆菌表达系统成功克隆并纯化了重组人DCK蛋白，验证了其磷酸化脱氧胞苷的酶活性，为后续抗癌药物代谢研究提供基础。
2. **《DCK重组蛋白在核苷类似物药物筛选中的应用》**
- 作者：Chen L, et al.
- 摘要：利用重组DCK蛋白建立体外酶活性检测模型，评估多种核苷类似物(如吉西他滨)的磷酸化效率，揭示其在癌症化疗中的潜在应用价值。
3. **《Structural and functional characterization of recombinant human deoxycytidine kinase》**
- 作者：Johansson M, et al.
- 摘要：通过X射线晶体学解析重组人DCK的三维结构，结合酶动力学实验阐明其底物结合机制及突变对药物敏感性的影响。
4. **《腺病毒载体介导的DCK基因递送增强肿瘤细胞对核苷类药物的敏感性》**
- 作者：王敏等
- 摘要：构建携带重组DCK基因的腺病毒载体，证明其在肿瘤细胞中过表达可显著提高吉西他滨的细胞毒性，为基因治疗提供新策略。
**提示**：以上为示例性内容，实际文献需通过PubMed、Google Scholar等平台以“recombinant DCK protein”“deoxycytidine kinase expression”等关键词检索确认。
**Background of Recombinant DCK Protein**
Deoxycytidine kinase (DCK) is a critical enzyme in the nucleotide salvage pathway, responsible for phosphorylating deoxycytidine and specific nucleoside analogs, a key step in their activation as antiviral or anticancer agents. It plays a vital role in DNA synthesis and the metabolism of nucleoside-based therapeutics, such as gemcitabine and cytarabine, commonly used in chemotherapy. DCK deficiency is linked to drug resistance in cancer treatment, highlighting its clinical relevance.
Recombinant DCK protein is engineered via genetic cloning, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems to ensure proper folding and enzymatic activity. Its production enables large-scale studies on enzyme kinetics, substrate specificity, and interactions with therapeutic nucleosides. Researchers utilize recombinant DCK to screen for novel prodrugs, optimize chemotherapeutic efficacy, and investigate mechanisms underlying drug resistance.
In cancer research, DCK’s role in activating prodrugs has driven interest in its recombinant form for *in vitro* drug sensitivity assays and personalized medicine approaches. Structural studies using recombinant DCK, aided by X-ray crystallography, have revealed insights into its catalytic mechanism and substrate-binding domains, guiding the design of targeted therapies. Additionally, DCK is explored in gene therapy, where its expression is combined with suicide genes (e.g., HSV-TK) to enhance prodrug activation in cancer cells.
Overall, recombinant DCK serves as a vital tool in oncology and virology, bridging biochemical research with therapeutic innovation. Its applications span drug development, mechanistic studies, and translational strategies to overcome treatment resistance.
×
